Pharmaceuticals

A Chinese biotech is pioneering next-gen cancer drugs that promise higher precision and fewer side effects. Is this the future of oncology treatment?

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

A newly validated 'longevity protein' is fueling a biotech gold rush, but can companies turn breakthrough science into viable medicine? An inside look.

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

Trinity Consultants' acquisition of CEQA/NEPA expert Meridian is more than a regional deal; it's a strategic move with deep implications for biopharma.

Stunning trial data reveals an immunotherapy combo that slashes myeloma progression by 83%, offering not just longer life but a better quality of life.

LRN appoints Bob Lemmond as CEO, a strategic move signaling a deeper push into data-driven ethics amid rising AI regulations and market complexity.

Beyond a simple product launch, a strategic acquisition is fueling innovations in drug delivery that could transform patient care for millions worldwide.

A new narcolepsy drug could finally offer patients what they've been missing: a single nightly dose with low sodium, transforming lives and the market.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

Eli Lilly's groundbreaking leukemia drug data signals a major market shift, promising better patient outcomes and fortifying its long-term growth strategy.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Animal health giant Elanco is restructuring its global footprint, betting its future on a U.S.-centric innovation pipeline and blockbuster pet health drugs.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.

A new lab system combines speed, multiplexing, and regulatory trust, promising to accelerate drug development and deepen our biological understanding.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

A top global forum warns of politicized trade and tech divides. How will this impact pharma supply chains, AI in medicine, and market access?